The Trump administration made a significant announcement on Thursday regarding a deal with Novo Nordisk and Eli Lilly to expand access to popular obesity drugs. The deal aims to provide more coverage for Medicare and Medicaid beneficiaries and lower the prices of these drugs.
According to senior administration officials, the administration views this expansion of access to obesity drugs as a major win in the fight against chronic disease. While the exact timeline for the coverage expansion and the specific beneficiaries who will gain access have not been fully disclosed, Medicare and Medicaid will receive substantial discounts on the drugs.
Under the terms of the deal, the drugs will be sold for $245 a month across both programs for weight loss and diabetes treatment. Medicare beneficiaries will have a $50 copay for these medications. This move is expected to help individuals with overweight or obesity to lose weight and manage their diabetes more effectively.
The administration believes that by providing more people with access to these drugs, it will lead to better health outcomes and lower healthcare costs in the long run. This initiative underscores the administration’s commitment to improving the health and well-being of Americans, particularly those struggling with chronic conditions like obesity and diabetes.
It is important to note that this article is exclusive to STAT+ subscribers. To access the full content and daily market-moving biopharma analysis, readers are encouraged to subscribe to STAT+. By subscribing, readers can stay informed about the latest developments in the healthcare industry and gain valuable insights into the future of healthcare.
